Company Profile

AlphaMed Inc
Profile last edited on: 12/19/14      CAGE: 3BUP7      UEI: C3MNNDBRLP89

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1997
First Award
2004
Latest Award
2009
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

PO Box 607
Acton, MA 01720
   (978) 929-9190
   N/A
   www.alphamed.biz
Location: Single
Congr. District: 03
County: Middlesex

Public Profile

AlphaMed develops and markets isotopes using photonuclear technology. Agreements are in place with Rensselaer Polytechnic Institute for irradiation services and with the Pacific Northwest National Lab to process AlphaMed's isotopes and prepare them for shipment. The company has relationships with Argonne National Laboratory and is developing relationships with selected Russian laboratories under the Initiatives for Proliferation Prevention program. AlphaMed is a member of the United States Industry Coalition, Inc., a non-profit association of U.S. companies and universities dedicated to the nonproliferation of weapons of mass destruction through commercialization of technologies for peaceful purposes

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 2 NIH $854,507
Project Title: Production and use of Pb-203 for cancer therapy research
2009 1 NIH $111,339
Project Title: A PB-212 Generator using Resistant Substrate and RN Cold Trapping
2009 1 NIH $150,000
Project Title: Biomedical (Basic)
2007 1 NIH $115,953
Project Title: Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells
2007 1 NIH $111,300
Project Title: Processing Ac-227 sources for lead-212 and radium-223 required by cancer research

Key People / Management

  Richard F Testa -- President

  Aaron Bertrand Brill

  Cathy S Cutler

  Gary John Ehrhardt

  Herbert A Moore

  Chuck Z Soderquist

Company News

There are no news available.